Special Issue "Artemisinin (Qinghaosu): Commemorative Issue in Honor of Professor Youyou Tu on the Occasion of Her 80th Anniversary" in International Molecules Published in 2010.

It has been more than 10 years since we published the Special Issue "Artemisinin (Qinghaosu): commemorative issue in honor of Professor Youyou Tu on the occasion of her 80th anniversary" (Abbreviated as "the Artemisinins Special Issue") [...].

Tu Youyou winning the Nobel Prize: Ethical research on the value and safety of traditional Chinese medicine.

In 2015, the Chinese pharmacologist, Tu Youyou, was awarded the Nobel Prize for Physiology or Medicine for the discovery of artemisinin. Traditional Chinese medicine (TCM) was the source of inspiration for Tu's discovery and provides an opportunity for the world to know more about TCM as a source of medical knowledge and practice. In this article, the value of TCM is evaluated from an ethical perspective. The characteristics of 'jian, bian, yan, lian' are explored in the way they promote accessibility and economic efficiency for TCM. The article also examines how the increased use and prevalence of TCM reflects the scientific, cultural, and ethical values of TCM and their increasing attraction in meeting major challenges to medicine and health systems currently and in the future. The article discusses safety issues within TCM, which is a controversial area, and also comments on some shortcomings and challenges which pose difficulties for more widespread and greater uptake of TCM-derived clinical or therapeutic interventions. The article concludes that TCM is generally safe if it is used according to TCM theory and where such applications are cognizant of the strengths and weaknesses of TCM. TCM has important bioethical values which may inform potential measures for meeting challenges facing global health care systems and the article argues that it can have an increasing role in improving human health.

Synthetic Strategies for Peroxide Ring Construction in Artemisinin.

The present review summarizes publications on the artemisinin peroxide fragment synthesis from 1983 to 2016. The data are classified according to the structures of a precursor used in the key peroxidation step of artemisinin peroxide cycle synthesis. The first part of the review comprises the construction of artemisinin peroxide fragment in total syntheses, in which peroxide artemisinin ring resulted from reactions of unsaturated keto derivatives with singlet oxygen or ozone. In the second part, the methods of artemisinin synthesis based on transformations of dihydroartemisinic acid are highlighted.

The story of artesunate-mefloquine (ASMQ), innovative partnerships in drug development: case study.

BACKGROUND: The Drugs for Neglected Diseases initiative (DNDi) is a not-for profit organization committed to providing affordable medicines and access to treatments in resource-poor settings. Traditionally drug development has happened "in house" within pharmaceutical companies, with research and development costs ultimately recuperated through drug sales. The development of drugs for the treatment of neglected tropical diseases requires a completely different model that goes beyond the scope of market-driven research and development. Artesunate and mefloquine are well-established drugs for the treatment of uncomplicated malaria, with a strong safety record based on many years of field-based studies and use. The administration of such artemisinin-based combination therapy in a fixed-dose combination is expected to improve patient compliance and to reduce the risk of emerging drug resistance. CASE DESCRIPTION: DNDi developed an innovative approach to drug development, reliant on strong collaborations with a wide range of partners from the commercial world, academia, government institutions and NGOs, each of which had a specific role to play in the development of a fixed dose combination of artesunate and mefloquine. DISCUSSION AND EVALUATION: DNDi undertook the development of a fixed-dose combination of artesunate with mefloquine. Partnerships were formed across five continents, addressing formulation, control and production through to clinical trials and product registration, resulting in a safe and efficacious fixed dose combination treatment which is now available to treat patients in resource-poor settings. The south-south technology transfer of production from Farmanguinhos/Fiocruz in Brazil to Cipla Ltd in India was the first of its kind. Of additional benefit was the increased capacity within the knowledge base and infrastructure in developing countries. CONCLUSIONS: This collaborative approach to drug development involving international partnerships and independent funding mechanisms is a powerful new way to develop drugs for tropical diseases.

From bark to weed: the history of artemisinin.

In the 1970's, in China, some brilliant and courageous scientists carried out a research programme, which lead to the discovery of artemisinin derivatives and new quinoleines that are used today, in combination, as first line treatment of malaria.

A brief history of malaria chemotherapy.

Malaria is one of the worst sicknesses to affect humankind. For centuries there was no specific treatment, and it was not until the seventeenth century that Spanish colonisers brought back from Peru tree bark from which quinine was later extracted. In the twentieth century, synthetic alternatives to quinine were developed. Of these, chloroquine was the most successful, but by the 1970s widespread resistance had developed and the world was left without an effective treatment for malaria. During the same decade Chinese scientists extracted from sweet wormwood plant the drug artemisinin, which has proved to be very effective against chloroquine-resistant malarial parasites. The use of a combination therapy including artemisinin has made it possible to contemplate the eradication of malaria. Efforts to produce a stable and inexpensive supply of artemisinin are under way.

Diverse biologies and experiential continuities: did the ancient Chinese know that qinghao had anti-malarial properties?

This article treats Chinese medical theories and concepts as cultural constructs that arose as much from practice-oriented concerns as from socio-political negotiations within the medical field. It further explores the interface of the biological and cultural. It is often futile to investigate how Chinese medical descriptions relate to biological processes, because the local biologies that the Chinese physicians recognized in the past and continue to describe in the present, are contested by mainstream medicine, but recent bioscientific research on the anti-malarial properties of the Chinese medical drug qinghao opens up new avenues for the historian. To be sure, no attempt is made to equate ancient nosologies to modern ones, nor to justify the cultural through the biological. In order to avoid pitfalls of simple equations, this article takes the experiential not merely as a subjective but as an inter-subjective reality that mediates the biological and cultural. The findings are striking: once one reads the Chinese medical texts as reporting on the experiential, one of their many possible readings is that they provide concrete descriptions of morbid conditions that also the contemporary mainstream physician recognizes.

Artemisinins from folklore to modern medicine--transforming an herbal extract to life-saving drugs.

The history of the artemisinins from Ge Hong in China during the 4th century, to the re-discovery of the qing hao derivatives in the 1970s, to the explosion of artemisinin derivatives and combinations throughout the world today is a fascinating story. The central and underappreciated role of the United States Army's 'drug company' known as the Division of Experimental Therapeutics at the Walter Reed Army Institute of Research is a story worth relating. From being the first group outside China to extract the active component of qing hao, to leading the work on neurotoxicity of the class in animals, to bringing a Good Manufacturing Practices intravenous formulation to the worldwide market is traced.

[Retrospection on the history of discovery of artemisinin and its ponderation].

The study of the medical history of the discovery of artemisinin is divided into two stages since its achievement of international awards. Before the award, the studies were focused on historical background, discoverer, time of discovery, discovery process, methodology, key difficulties, and the disputes about artemisinin and its causes. After achieving international awards, the focus of research was obviously different. In addition to more detailed research on the discovery process, more researches were focused on a multiple approach, including the significance, enlightenment, experience and lessons of discovery of artemisinin, scientist community, Tu Youyou's award-winning priority, Tu Youyou's biography, involving the spread, right of discovery and inventory, and geography of science and technology. In the future, scientific methodology, unconventional thoughts, intuitive thoughts, abductive reasoning, special social background at that time and the thought leading to its ponderation, etc. of winning the Nobel Prize should all be paid attention to.

The history of qing hao in the Chinese materia medica.

Artemisinin is currently used for treating drug-resistant malaria. It is found in Artemisia annua and also in A. apiacea and A. lancea. Artemisia annua and A. apiacea were known to the Chinese in antiquity and, since they were easily confused with each other, both provided plant material for the herbal drug qing hao (blue-green hao). This article shows, however, that since at least the eleventh century Chinese scholars recognized the difference between the two species, and advocated the use of A. apiacea, rather than A. annua for 'treating lingering heat in joints and bones' and 'exhaustion due to heat/fevers'. The article furthermore provides a literal translation of the method of preparing qing hao for treating intermittent fever episodes, as advocated by the eminent physician Ge Hong in the fourth century CE. His recommendation was to soak the fresh plant in cold water, wring it out and ingest the expressed juice in its raw state. Both findings may have important practical implications for current traditional usage of the plant as an antimalarial: rather than using the dried leaves of A. annua in warm infusions, it suggests that fresh juice extraction from A. apiacea may improve efficacy.

A Brief History of Qinghaosu.

The 2015 Nobel Prize for Medicine or Physiology was awarded to William C. Campbell and Satoshi Omura for their discovery of avermectins, and to Tu You You for her contribution to the discovery of artemisinin. The discovery and development of qinghaosu (artemisinin) as an antimalarial drug is a remarkable and convoluted tale.

Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance.

The emergence and spread of antimalarial resistance has been a major liability for malaria control. The spread of chloroquine-resistant Plasmodium falciparum strains had catastrophic consequences for people in malaria-endemic regions, particularly in sub-Saharan Africa. The recent emergence of artemisinin-resistant P. falciparum strains is of highest concern. Current efforts to contain artemisinin resistance have yet to show success. In the absence of more promising plans, it has been suggested to eliminate falciparum malaria from foci of artemisinin resistance using a multipronged approach, including mass drug administrations. The use of mass drug administrations is controversial as it increases drug pressure. Based on current knowledge it is difficult to conceptualize how targeted malaria elimination could contribute to artemisinin resistance, provided a full treatment course is ensured.